[Retrospective clinical evaluation of prognosis factors in stage D2 prostatic cancer treated with endocrine therapy].
Of 91 patients with prostatic cancer treated at our Department of Urology, from January 1976 through December 1987, 42 cases of stage D2 cancer treated with endocrine therapy were evaluated retrospectively with regard to clinical parameters and prognoses. The patients with marked increase in the level of the prostatic acid phosphatase (PACP), and the lactate dehydrogenase (LDH) in serum, and marked decrease in volume of hemoglobin (Hb) had a poor prognosis. The patients who took a long time to obtain a favorable response to the therapy had a poor prognosis. The response grade in NPCP criteria at 3 months after the initiation of therapy reflected the prognosis, and showed good correlation to the grade of favorable response.
Kudo
K
K
Department of Urology, Kyorin University School of Medicine.
Nagata
M
M
Hayashi
N
N
Imamura
H
H
Kimura
M
M
Mimura
H
H
Matsuyama
K
K
Shishido
S
S
Chino
I
I
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D002715:Chlormadinone Acetate / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate
D006454:Hemoglobins; D002715:Chlormadinone Acetate; D004054:Diethylstilbestrol; D007770:L-Lactate Dehydrogenase; D000135:Acid Phosphatase